Prostate Cancer

Prostate Cancer Lab #50: Cancer Vaccines (Lisa Butterfield) [Video]

Prostate Cancer Lab #50: Cancer Vaccines (Lisa Butterfield)

Advanced cancer patients see immunotherapies as offering one of the best paths to a durable response. Cancer vaccines have a lot of potential because they offer a possible treatment option to nearly every cancer patient. And immunotherapies offer the promise of durable responses — they are fighting a biological system (the cancer) with another system (the immune system), rather than the hit and miss, less durable paradigm of targeting a biomarker with a single drug.

00:00:00 Meeting Introduction
00:02:00 Can Cancer Vaccines Really Work?
00:02:21 Disclosures
00:02:39 Cancer Vaccines Are Showing Promise. Here’s How They Work
00:02:52 mRNA Vaccine Combinations
00:03:39 Common Cancer Drivers
00:03:54 The Classics: Commonly Targeted Shared Tumor Antigens
00:04:11 Tumor Antigens
00:04:33 Tumor Cells are Poor APC
00:05:11 Timeline of Cancer Vaccine Development
00:05:21 FDA Approved (mCRPC)
00:05:56 Tumor Antigens
00:06:21 Three Phases of the Cancer Immuno-editing
00:07:01 T Cell Exhaustion
00:08:09 Vaccine Platforms
00:08:14 Dendritic Cells
00:08:46 Dendritic Cell Vaccines
00:08:54 Why Dendritic Cell Vaccines?
00:09:24 Antigen Delivery to Dendritic Cells and Patient Response
00:10:07 Epitope Spreading
00:11:17 What Have Vaccines Been Shown to Do?
00:11:40 Tumor Mutations
00:12:35 Neoantigens
00:13:15 Tesla Project (neoepitope pipelines)
00:14:08 Autologous Tumor Lysate-Loaded Dendritic Cell (Brain Tumors)
00:14:47 RNA Vaccines
00:15:17 Neoantigen T Cells
00:15:53 Porter Prostate Cancer Trial
00:18:14 Summary of Porter Findings
00:19:49 Summary of Companies Involved in Cancer Vaccine Trials
00:20:29 The Dawn of Vaccines for Cancer Prevention
00:21:12 Q&A

Lisa Butterfield, PhD, Consultant in Immuno-Oncology, Adjunct Professor of Microbiology and Immunology, University of California San Francisco, is uniquely positioned to share the state of the art on cancer vaccines. Besides being a leading researcher, she brings the patient and caregiver perspective. Her husband had pancreatic cancer, and she was his patient advocate and caregiver. She experienced the extremely difficult challenges of trying to navigate this for him.

“In cancer vaccines people have been looking for targets – things that are different between the patient and the tumor. And there are a lot of targets. For a long time, these targets were sort of old timey things like PSMA and PSA, which are known to be overexpressed by a [prostate cancer] tumor, that we would try to target the immune system against. And the response has been okay, but not great.” – Lisa Butterfield

Watch/Read More
Prostate Cancer

Community Conversations: Prostate Cancer Awareness [Video]

September is Prostate Cancer Awareness Month – the second most common type of cancer in men in the United States. Join Atlantic Health System urologist Dr. Naeem Rahman to discuss the importance of early detection and regular checkups.Thursday, September 14th at 12:30pmNaeem Rahman, MD, Medical Director, Atlantic Medical Group Urology

Prostate Cancer

Man shares journey to raise Prostate Cancer Awareness Month awareness [Video]

Richard Benevento, 67, doesnt like saying the word cancer.I dont know if that was a denial thing or not, he said. But now, more than four years after his prostate cancer diagnosis, which is the second leading cause of cancer death for American men, Benevento is sharing his story. He is saying the word cancer to encourage men to talk with their doctor about getting screened. If you live in Boston, youre in the medical capital of the world. Why not take advantage of these things to improve your quality of life and extend your life? he asked. Part of Beneventos treatment was at the Massachusetts General Cancer Center with Dr. Sophia Kamran.Theres still some stigma surrounding prostate cancer and prostate cancer diagnosis, Kamran, a radiation oncologist at Massachusetts General Cancer Center, said.Kamran said treatments have come a long way and that the prostate-specific antigen test PSA remains the gold standard for early detection.We generally recommend for average-risk men that they start talking to their doctor about it at age 45-50, Kamran said. Those at higher risk include Black men and men with a family history not just of prostate cancer, but other types of cancer.Benevento said the talk wasnt just for him but also for his family, and he hopes men decide to have that conversation now, with September being Prostate Cancer Awareness Month.I got stuff to do, you know what I mean? Im not ready to check out. So again, if someone is watching this, get checked, Benevento said.Kamran adds that for Black men, its important to talk with their doctor not only because they are at higher risk of having a prostate cancer diagnosis but also because they are at higher risk of death from prostate cancer.